Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded at Wedbush

Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a neutral rating to an outperform rating in a report released on Tuesday morning, MarketBeat.com reports. They currently have $6.00 target price on the stock, up from their prior target price of $5.00.

Other analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, October 19th. Jefferies Financial Group raised shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 14th. William Blair began coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating for the company. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Leerink Partners assumed coverage on Zentalis Pharmaceuticals in a research note on Monday, October 5th. They issued an “outperform” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.29.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $1.68 on Tuesday. The stock has a fifty day moving average of $2.58 and a 200-day moving average of $3.39. Zentalis Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $6.95. The stock has a market cap of $120.41 million, a PE ratio of -0.88 and a beta of 1.91.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.20. On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -1.85 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. Russell Investments Group Ltd. lifted its holdings in Zentalis Pharmaceuticals by 1,834.6% during the third quarter. Russell Investments Group Ltd. now owns 77,383 shares of the company’s stock valued at $214,000 after purchasing an additional 73,383 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $122,000. Eiger Wealth Management LLC grew its stake in Zentalis Pharmaceuticals by 33.8% during the 3rd quarter. Eiger Wealth Management LLC now owns 115,112 shares of the company’s stock worth $319,000 after purchasing an additional 29,095 shares in the last quarter. Spark Investment Management LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at about $61,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $126,000.

Key Zentalis Pharmaceuticals News

Investors following ZNTL have been watching these news items:

• Positive Sentiment: Wedbush upgraded its rating on ZNTL, another potentially supportive analyst signal; the report provided here does not specify the new rating. Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
• Neutral Sentiment: Morgan Stanley maintained its Hold rating, indicating a more cautious stance than HC Wainwright’s Buy view. Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for 2029 and 2030, signaling weaker expectations for those later years and tempering the improved nearer-term outlook. MarketBeat ZNTL coverage

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.